The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

2 Oct 2014 07:00

RNS Number : 2307T
Premaitha Health PLC
02 October 2014
 



 

2 October 2014

Premaitha Health PLC

("the Company")

 

Grant of Options  

Premaitha Health PLC, a molecular diagnostics company employing next generation DNA analysis technology to develop molecular diagnostic products, announces that, further to the disclosure made in the Company's admission document dated 13 June 2014, it has granted options to subscribe for ordinary shares of 10p each in the Company ("Ordinary Shares"), exercisable at a price of 10p per share, to the following directors of the Company:

Director No of options

Dr Stephen Little 10,555,984

Peter Collins 5,638,174

 

The options above are granted under the Company's unapproved option scheme and will only vest if there is a positive movement in earnings per share. The options become exercisable in respect of one third of the Ordinary Shares over which they are granted on the first, second and third anniversaries of the date of grant.

 

In addition, the Company has granted a further 11,769,638 options to staff and senior management to subscribe for Ordinary Shares under the Company's EMI scheme. The options are subject to the same vesting conditions as those of the directors above.

 

The total number of options granted is therefore 27,963,796, which represents 14.9 per cent. of the Company's existing ordinary share capital. This number is greater than the number of options as set out on page 132 of the admission document dated 13 June 2014 following a meeting of the remuneration committee.

 

-Ends-

 

For more information, please contact:

 

 

Premaitha Health plcDr Stephen Little, Chief Executive OfficerJoanne Cross, Marketing Communications

Tel: +44 (0) 7736 843052Email: investors@premaitha.com

 

 

Cairn Financial Advisers LLP (NOMAD)Liam MurrayAvi Robinson

  Tel: +44 (0) 20 7148 7900

 

 

Panmure Gordon (UK) Limited (Broker)Robert NaylorFreddy Crossley 

 

 Tel: +44 (0) 20 7886 2500

Instinctif Partners (Media)Melanie Toyne Sewell / Jen Lewis

 

Tel: +44 (0) 207 457 2020

premaitha@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBRBDGISGBGSB
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.